Next Article in Journal
Does COVID-19 Really Exacerbate Urticaria? A Survey of 166 Patients in China
Previous Article in Journal
Service Uptake Challenges Experienced by Pasifika Communities during COVID-19 Lockdowns in New Zealand
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Relationship between BMI and COVID-19

1
Quality of Life in the Rural World (Q-Rural) – Research Unit, Polytechnic Institute of Castelo Branco, 6001-909 Castelo Branco, Portugal
2
Dr. Lopes Dias Higher School of Health, Polytechnic Institute of Castelo Branco, 6001-909 Castelo Branco, Portugal
3
Higher School of Agriculture, Polytechnic Institute of Castelo Branco, 6001-909 Castelo Branco, Portugal
4
Higher School of Health Technologies, Polytechnic Institute of Coimbra, 3000-239 Coimbra, Portugal
*
Author to whom correspondence should be addressed.
COVID 2023, 3(11), 1698-1706; https://doi.org/10.3390/covid3110117
Submission received: 30 October 2023 / Revised: 12 November 2023 / Accepted: 16 November 2023 / Published: 19 November 2023

Abstract

:
Body mass index has been studied as one of the factors that negatively influences COVID-19. In this work, we intend to analyze this influence. A representative sample of the population of Beira Interior was used (around 2%), on which immunity research and a socio-demographic survey were carried out. It was found that obesity influences the vaccination rate, and that all other variables analyzed were not influenced by body mass index.

1. Introduction

COVID-19 is a pathology that took the entire planet by surprise with its ability to transmit itself to all countries very quickly, putting the entire scientific community into shock [1].
Its origin still requires more concrete studies, but everything suggests that it was a transmission of a virus from animals to humans, with known catastrophic effects.
COVID-19, in addition to the deaths it caused in the human population, also contributed to the exhaustion of health systems worldwide and thus was responsible for many other deaths, indirectly, because there was no space and capacity to, for example, perform cancer screening programs [1].
COVID-19 is an infectious respiratory disease, associated with SARS-CoV-2, a virus belonging to the coronavirus group. These have been known for more than 60 years and have a huge history of infections in both humans and animals but have always been associated with mild respiratory infections and without great significance from the point of view of negative evolution. Children have always appeared as the most prevalent group, particularly those of younger ages [2].
However, it is important to remember that there were coronaviruses associated with more serious pathologies, such as severe acute respiratory syndrome (SARS), which began to spread in 2002 from China and was controlled in 2004. Later, in 2012, a new virus emerged, particularly in Saudi Arabia and neighboring countries, which was designated as Middle East respiratory syndrome [3].
Thus, the most common coronaviruses in general are associated with respiratory infections in human beings, which can be classified, in the majority, as mild or moderate. The main symptoms are cough, sore throat, and increased body temperature. In situations of greater vulnerability of the infected human being, viruses may be able to reach the lower respiratory tree, thus invading the lungs and causing viral pneumonia. This vulnerability is usually associated with cardiovascular diseases, low immunity (associated with several underlying pathologies), and metabolic diseases, in which, in addition to diabetes, obesity may also be considered. There are additionally other conditions that can contribute to a negative outcome, such as age (in this case, the explanation could be a more exhausted immune system, for example) [4].
The usual incubation period varies from between 2 and 14 days. The period of transmission is associated with the period of symptoms (including symptoms that can contribute to spread, such as coughing, for example), but it is important to highlight that in other phases of the disease it is also possible to have contamination from other human beings [4].
This contamination occurs through direct contact between human beings, but there is also a description of transmission through contaminated surfaces. All human behaviors that may contribute to an increase in the number of people in the same space, decreased ventilation, or crowding, represent increased risks [1].
The diagnosis of COVID-19 can be made after medical evaluation and by carrying out the nucleic acid amplification test (TAAN): for the detection of virus RNA, carried out with samples collected through a swab from the nose and/or the throat or the rapid antigen test (TRAg), which are proximity tests carried out with samples collected through a swab from the nose and/or throat region [5].
It is possible to prevent the transmission of SARS-CoV-2, employing various methodologies, such as the use of a mask, the adoption of respiratory etiquette (when coughing or sneezing, covering your nose and mouth with a tissue or your arm and then throwing the tissue in the trash and washing your hands, or using an alcohol solution with at least 60% alcohol), washing and/or disinfecting your hands frequently, cleaning and disinfecting equipment and surfaces, especially those that are most touched, maintaining physical distancing and avoiding closed or crowded environments, keeping spaces ventilated, preferably through natural ventilation, opening doors and/or windows, and vaccination [6].
Vaccines were one of the main turning points in the COVID-19 pathology, as they contributed very effectively to the ending of the pandemic. From the existing knowledge in science, there are several main approaches to designing a vaccine. The differences are based on the methodology used: using an entire virus or bacteria that transmits the disease, or a very similar one, and inactivating or killing it using chemicals, heat, or radiation. This approach uses technology that has been proven to work on humans. However, it requires special laboratory facilities to safely grow the virus or bacteria, can have a relatively long production time, and will likely require the administration of two or three doses; similarly, a live but weakened version of the virus or a very similar version can be used. This approach uses technology similar to the inactivated vaccine and can be manufactured on a large scale. However, vaccines like this may not be suitable for people with compromised immune systems. On the other hand, it is possible to use only components that awaken the immune system and use genetic material that provides instructions for the production of specific proteins and not the entire virus. This type of vaccine uses a safe virus to deliver specific subparts—called proteins—so that it can trigger an immune response without causing disease. To do this, instructions for producing specific parts of the target of interest are inserted into a secure virus. The safe virus then serves as a platform or vector to deliver the protein to the body. The protein triggers the immune response. There is also the possibility of a subunit vaccine, which uses only very specific parts (the subunits) of a virus or bacteria that the immune system needs to recognize. It does not contain the complete microorganism, nor does it use a virus as a vector. Unlike vaccine approaches that use an entire weakened or killed microorganism or parts of one, a nucleic acid vaccine uses only a section of genetic material that provides the instructions for specific proteins. DNA and RNA are the instructions our cells use to make proteins. In our cells, DNA is first transformed into messenger RNA, which is then used as a template to produce specific proteins. A nucleic acid vaccine delivers a specific set of instructions to our cells, either as DNA or mRNA, to produce the specific protein that we want our immune system to recognize and respond to. The nucleic acid approach is a new way to develop vaccines. Before the COVID-19 pandemic, none of these approaches had yet gone through the full approval process for use in humans, although some DNA vaccines, including for specific cancers, were undergoing human trials. Due to the pandemic, research in this area has progressed very quickly and some mRNA vaccines for COVID-19 are receiving emergency use authorization, meaning they can now be administered to people in addition to only being used in clinical trials [7,8,9].
The COVID-19 pandemic revealed several phases along its path, being a constant and permanent learning process. As the pathology advanced, science also expanded our knowledge, from the form of transmission, through treatments and prevention, particularly with the creation of vaccines, which revolutionized the transmission route of SARS-CoV-2.
There are underlying diseases that predispose patients to greater severity, such as high blood pressure, cardiovascular problems, asthma and obesity, among others [1], but there are also genetic changes that can contribute to a negative evolution of the pathology [10,11]. People who had one of these previous pathologies were always the most affected, with much more severe effects, but there are also reports of negative developments in people, who initially did not have associated risk factors.
On the other hand, there are some factors that can act as a protection against negative developments, such as the individual’s healthy state and previous vaccination [12]. In addition to what was previously described, people with good prognostic factors developed negatively, without any apparent justification.
The relationship between body mass index and the consequences of COVID-19 has often been explored and analyzed, in order to understand the implications for the natural evolution of the disease and long-term COVID. Increasing knowledge about the pathology caused by SAR-COV-2 is a scientific imperative and many studies have been carried out in this field [13], which have proven to be indispensable for increasing control and treatment capacity.

2. Objective

Analyze the influence of body mass index on the pathology caused by SARS-CoV-2.

3. Materials and Methods

The Beira Baixa com Vida Project, where this work was carried out, arose from the need to monitor and evaluate the influence of SARS-CoV-2 in a region in the interior of Portugal, with a low population density and where the population is experiencing increasing difficulties in accessing health.
To carry out this work, integrated into the Beira Baixa com Vida Project, 1552 individuals were involved. A whole blood sample was collected to assess immunity and a socio-demographic survey was carried out (sex, weight, height, BMI, previous pathology, symptoms during COVID-19, vaccination for SARS-CoV-2, test RT-PCR for SARS-CoV-2). The time range was set between November 2020 and June 2023.
The BMI classification was based on five subtypes: normal, overweight, grade I obesity, grade II obesity, and morbid obesity, in accordance with other articles in the area [14] and with European WHO guidelines (https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index. accessed on 15 September 2023). Body mass index was calculated following the standards defined by the World Health Organization (WHO).
Immunity was assessed by searching for antibodies using the YHLO UNICELL system. According to the manufacturer’s instructions, an individual is considered to have a concentration of neutralizing antibodies sufficient to confer immunity against SARS-CoV-2 when this is greater than ten AU/mL.
Symptoms were analyzed individually and organized into four levels, according to the existing bibliography: asymptomatic, mild, moderate and severe [15].
Information was collected by a “self-report”, in accordance with practices used in other similar projects [16]. This type of information collection allows the individual to explain in detail the pathologies they have.
The Ethics Committee of the Polytechnic Institute of Castelo Branco approved this study on 14 July 2021 (33/CE-IPCB 2021). All subjects consented to the research, including personal and health data as well as the collection of a venous blood sample. All individuals had access to the theoretical part of the project, read and filled out the “informed consent” form and were informed that they could withdraw from the project at any time, without any consequences. All the most correct ethical precepts were taken into consideration and the Declaration of Helsinki was respected.

4. Results

The sample consisted of 1552 individuals, 64% male and the remaining 36% female. It had an average age of 48.95 years, with a minimum of 18 and a maximum of 98 years.
According to the body mass index classification defined in five levels, it was observed that 41.4% of the sample was of normal weight, 37.4% was overweight, 15.0% was class I obese, while 3.2% was in class II obesity and 1.5% in morbid obesity. For 1.5% of the sample, it was not possible to calculate the value.
With regard to vaccination, 97.9% of individuals were vaccinated and the remaining 2.1% reported never having received any doses of the vaccine against SARS-CoV-2.
When analyzing the relationship between BMI and vaccination, we verified the existence of statistically significant differences, because individuals classified in the four highest categories make up a higher percentage of vaccinated people compared to individuals classified as “normal weight”.
On the subject of the type of vaccine (commercial brand) used, we observed that the majority of people were vaccinated with Comirnaty (PFIZER) (38.9%), 20.2% with Spikevax (Moderna), 11.7% with Vaxzevria (Astrazeneca), and 4.8% with the Janssen vaccine. The remaining individuals took doses combining different types of vaccines, with an emphasis on 10.4% with Vaxzevria and Comirnaty, 7.2% with Vaxzevria and Spikevax, 2.8% with Janssen and Comirnaty, 2.6% with Janssen and Spikevax and 1.4% with Spikevax and Comirnaty. If we analyze these data taking into account body mass index, we observe that there are no statistically significant differences between the types of vaccine administered.
Regarding the previous existence of a positive COVID-19 RT-PCR test, it was observed that 32.3% of individuals had previously tested positive (501 people), indicating that they had had a SARS-CoV-2 pathology. It was further observed that there are no statistically significant differences.
With reference to the symptoms developed by individuals with a positive RT-PCR test, it is clear that only a small fraction (14.6%) was asymptomatic; 69.8% had mild symptoms, 14.2% moderate, and 1.4% severe symptoms. No statistically significant differences were observed in the analysis of BMI by the symptomatology developed.
Analyzing the specific symptoms during the COVID-19 pathology among the 501 individuals with a positive RT-PCR test result, it was observed that 63% had headaches, 55.9% had cough, 54% had odynophagia, 46% had gastrointestinal symptoms, 42.8% had an increase in temperature (above 37.5 °C), 37% had myalgia, 36.3% lost their sense of smell, and 15% had dyspnea.
Relating symptomatology to weight classification, it was observed that there are no statistically significant differences regarding the existence of symptoms (and type of symptoms), by BMI.
Among the people who reported a positive RT-PCR test, 7 individuals (1.4%) required hospitalization, with 57% classified as of normal weight and 43% as overweight, with no statistically significant relationship between these two variables.
A similar situation was recorded in admissions to the intensive care unit, in which only 2 individuals needed it (28%); one was classified as of normal weight and the other as overweight, with no significant differences being found, once again, in the relationship between BMI and the need for hospitalization in the ICU.
In the immunity analysis, it was found that 7.9% of the sample had an antibody value lower than the immunity threshold defined by the commercial house, with the remaining 92.1% having antibody levels higher than the minimum values proposed as a threshold of immunity. Analyzing this variable with the BMI classification, it was observed that there are no statistically significant differences.

5. Discussion

The work includes 1552 individuals, of whom 64% were male and the remaining 36% female. The sample had an average age of 48.95 years, with a minimum of 18 years and a maximum of 98 years. This sample was collected in the Beira Baixa region, which according to the most recent data available from the National Statistics Institute (online) consisted of 80,751 people, thus representing a sample very close to 2%; still according to this database, the majority of the population of Beira Interior was between 15 and 64 years old, with a predominance of women [17].
In this study, the predominance of males was notable, and it was probably men who were most alerted to the possibility of participating in this study, which has also been commonly found in other similar studies [18]. Regarding the age group, there is an alignment with the standard values for this population. We highlight the existence of several very old people (over 85 years old), which is an accurate portrait of the population of a rural location, such as this region represents.
More than half of the sample population (58.6%) was outside the “normal weight” standards, which is in line with other studies on obesity carried out in the Portuguese population [19,20,21].
Highlighting around 20% of the sample in obesity levels, as it is known from previous studies that this is one of the main factors in respiratory and cardiac pathologies, among others [22,23].
Body mass index is also known to be related to literacy levels, meaning that normally more rural populations with lower levels of access to healthcare, such as those living in Beira Baixa, tend to have lower levels of literacy and hence more than half of the population has a high BMI [24].
The vaccination rate found in this study was very high. One caveat is that the study began at the beginning of the implementation of the vaccination and continued until the WHO declared the end of the pandemic. Therefore, the data must be interpreted from this perspective, as they may naturally have fluctuated. A retrospective study analyzed vaccination intentions during the first year of the pandemic and values ranged between 27.7% and 93.3%. Considering that the work has gone through this phase, it is normal that the rate can be observed to be higher, especially because with the successive doses implemented, the Portuguese normally adhered to and reached high vaccination rates. A highlight, on the other hand, is an article from 2022 that analyzed the rate of hesitancy in vaccination against SARS-CoV-2 in 114 countries, which places Portugal with an acceptance rate of just 35%, in contrast to, for example, Canada (91%) and Norway (89%) [25].
Relating data on BMI and the vaccination rate, there are statistically significant differences, because individuals with BMI in the highest categories have a greater tendency to be vaccinated. Since the initial phase of the pandemic, obesity has been considered one of the most predisposing factors for negative developments during the course of COVID-19 [26]. Patients with a higher BMI had very high mortality levels when compared to individuals with a BMI classified as “normal”, whether associated with other pathologies or not [27]. It is probable that the sharing of this information either by health services or by the population itself may have contributed to greater availability of these individuals for the vaccination process. Obesity is associated with several other pathologies of a metabolic nature, which further increases the vulnerability of these patients but also its monitoring in health systems [28], and could therefore be a contribution to its higher vaccination rate.
We can observe that most people were vaccinated only with the Comirnaty vaccine (38.9%), or with this vaccine in combination with another (14.6%). In the case of a combined vaccine between two different ones, it is worth highlighting the fact that Comirnaty is always used in the second or third dose. Thus, more than half of our sample (53.5%) had contact with the Comirnaty vaccine throughout the vaccination process.
Analyzing several international studies, we observed that Comirnaty presented very high efficacy and safety values [29], which could be one of the justifications for these values. We recall that this vaccine was developed by a German technology company (BioNtech) and produced by a North American company (Pfizer), having been the first to obtain all the necessary authorizations for commercialization both in Europe and in the United States. It is based on mRNA, making it possible for there to be no dead or attenuated virus in its constitution, which also from the point of view of people with less literacy could be a positive factor for adherence to the vaccination [30].
Indeed, one of the biggest difficulties that the vaccination faced was people’s adherence to the process, with several obstacles being experienced. The constant misinformation and overvaluation of incidents that could possibly be related to the vaccination process were the most negative part. On the positive side, we can mention the hope that the creation of vaccines against COVID-19 has brought to humanity, as well as the tireless work of health professionals to demystify the process that led to the creation of vaccines in record time and their effectiveness as having been two of the greatest contributions to humanity in being able to combat this pandemic [31].
These issues became even more acute in the context of vaccinating children, with enormous doubts and fears on the part of parents, as they were always responsible for the final decision whether to vaccinate or not [32].
As previously mentioned, this work had a long duration, going through the various phases of the pandemic process. The existence of 32.3% of individuals with a positive RT-PCR test is a good example, since according to the most recent data from the General Directorate of Health (DGS), it is estimated that more than 5.5 million people have had contact with SARS-CoV-2 in Portugal (https://www.insa.min-saude.pt/category/areas-de-atuacao/epidemiologia/covid-19-curva-epidemica-e-parametros-de-transmissibilidade. Accessed on 15 September 2023), which represents a percentage of around 54% of the population residing in Portugal, considering the global value obtained in the 2021 census [33]. It is also important to highlight that, at this stage, the population uses “self-tests” much more, with no reporting of all cases, with the exception of those diagnosed in health units (concurrent with other health situations) or those that present severe symptoms [34]. Therefore, the value obtained in this study reflects, on average, the long trajectory and fluctuations that COVID-19 test reports have had, a consequence, naturally, of the evolution of the pandemic.
Analyzing the existence of a positive test by body mass index, we observed the non-existence of statistically significant differences. Contamination is associated with environmental factors, mainly closed spaces, contact with droplets of saliva and, in general, the proximity between individuals. Obesity is not, individually, a factor that contributes to increasing the probability of contamination by SARS-CoV-2, although it is, as we saw previously, a predisposing factor in situations of greater clinical severity [35].
In analyzing the symptoms, it was found that the most common symptoms were headache, cough and sore throat, which is similar to what has been described in most articles [36]. These symptoms were not related to BMI. When classifying the severity of the pathology according to the defined parameters, it was observed that the vast majority (69.8%) had a pathology classified as mild and only 1.4% required hospitalization, of whom 28% were in intensive care units. Once again, in this parameter, there are no statistically significant differences depending on body mass index, which is contrary to most studies carried out [37,38], that point to obesity as a potential negative impact on the favorable evolution of COVID-19, although science has not yet definitively explained the direct influence of obesity on the poor prognosis [39].
More than 92% of the sample showed antibody levels compatible with immunity. It was not possible to analyze how this immunity was obtained, specifically whether it was due to the vaccination process or whether it was related to immunity acquired through contact with SARS-CoV-2. Cross-referencing this data with the number of people who reported having had a positive RT-PCR test (32.3%) as well as the number of people vaccinated (97.9%), we can admit that the majority of individuals had an immune response. It should also be added that among the individuals who reported not having been vaccinated, 32% showed an immune response, that is, clearly associated with the previous presence of SARS-CoV-2 in the body. Vaccines present high levels of safety as well as similar side effects regardless of BMI [27], thus not constituting an increased risk due to the fact that they are administered to people with a high BMI.
It is known that vaccination contributes to reducing the risk of negative developments and these values are not influenced by BMI levels [39].

6. Conclusions

Considering the existing bibliography, this work may appear to be important because it provides increasing knowledge about the COVID-19 pathology in a specific area of Portugal, which has very particular characteristics, as it is located in the interior of the country, has enormous desertification, and a very low mortality rate. The population, is spread across a vast territorial area, with road access that is not always very capable of responding to its needs and with health institutions that often present real limitations in terms of human and technical resources.
With this work, we specifically intended to study one of the pathologies that has been most analyzed as a negative factor in the evolution of COVID-19. In fact, we realize that many studies have considered the relationship between this variable and the impact of SARS-CoV-2 infection, but at the same time there are many doubts that remain.
Among the main conclusions, it is observed that individuals with a higher BMI are more likely to be vaccinated against SARS-CoV-2. It is also observed that in the remaining parameters analyzed, namely in the severity of the pathology and associated symptoms, there were no statistically significant differences considering the stratification of the sample by BMI.
As the main limitations, we can highlight the duration of the data collection, due to the fact that it was a working basis obtained from the epidemic phase until mid-2023 and naturally the evaluation of the data had to take this factor into account. A limitation that could also be pointed out is the self-collection of information; however, this was explained throughout the work, and justified with the bibliography, and all the articles analyzed in this area were articles that used similar methodologies.
But the importance of being able to convey the various phases realistically is also an essential point, which should be valued. It also has the added value of being able to reflect, in a very approximate way, the reality of the population in which it operates.

Author Contributions

Conceptualization: F.R. and P.C.; methodology, M.M.; software, C.G.; validation, F.R. and P.C.; formal analysis, J.L.; investigation, I.R. and E.C.; resources, I.R. and E.C.; data curation, F.R.; writing—preparation of the original draft, J.L.; writing—review and editing, P.C.; visualization, M.M.; supervision, F.R.; acquisition of financing, all authors. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by COMPETE 2020—COVID-19 (AAC 02/SAICT/2020).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Polytechnic Institute of Castelo Branco on July 14 2021 (33/CE-IPCB 2021).

Informed Consent Statement

Informed consent was obtained from all individuals involved in the study, to whom the entire process of data collection, processing, analysis and dissemination was explained.

Data Availability Statement

There is a database created for this project, which can be consulted by researchers who demonstrate an interest.

Conflicts of Interest

The research team declares that it has no conflict of interest.

References

  1. Booth, A.; Reed, A.B.; Ponzo, S.; Yassaee, A.; Aral, M.; Plans, D.; Labrique, A.; Mohan, D. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS ONE 2021, 16, e0247461. [Google Scholar] [CrossRef] [PubMed]
  2. Zimmermann, P.; Curtis, N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr. Infect. Dis. J. 2020, 39, 355–368. [Google Scholar] [CrossRef] [PubMed]
  3. Zumla, A.; Hui, D.S.; Perlman, S. Middle East respiratory syndrome. Lancet 2015, 386, 995–1007. [Google Scholar] [CrossRef] [PubMed]
  4. Weaver, A.K.; Head, J.R.; Gould, C.F.; Carlton, E.J.; Remais, J.V. Environmental Factors Influencing COVID-19 Incidence and Severity. Annu. Rev. Public Health 2022, 43, 271–291. [Google Scholar] [CrossRef] [PubMed]
  5. Lai, C.K.C.; Lam, W. Laboratory testing for the diagnosis of COVID-19. Biochem. Biophys. Res. Commun. 2021, 538, 226–230. [Google Scholar] [CrossRef] [PubMed]
  6. Sharma, A.; Ahmad Farouk, I.; Lal, S.K. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses 2021, 13, 202. [Google Scholar] [CrossRef]
  7. Nakagami, H. Development of COVID-19 vaccines utilizing gene therapy technology. Int. Immunol. 2021, 33, 521–527. [Google Scholar] [CrossRef]
  8. Sharma, O.; Sultan, A.A.; Ding, H.; Triggle, C.R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 2020, 11, 585354. [Google Scholar] [CrossRef]
  9. Sumirtanurdin, R.; Barliana, M.I. Coronavirus Disease 2019 Vaccine Development: An Overview. Viral Immunol. 2021, 34, 134–144. [Google Scholar] [CrossRef]
  10. Gupta, K.; Kaur, G.; Pathak, T.; Banerjee, I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene 2022, 844, 146790. [Google Scholar] [CrossRef]
  11. Cappadona, C.; Rimoldi, V.; Paraboschi, E.M.; Asselta, R. Genetic susceptibility to severe COVID-19. Infect. Genet. Evol. 2023, 110, 105426. [Google Scholar] [CrossRef] [PubMed]
  12. Zhang, J.J.; Dong, X.; Liu, G.H.; Gao, Y.D. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin. Rev. Allergy Immunol. 2023, 64, 90–107. [Google Scholar] [CrossRef] [PubMed]
  13. Muralidar, S.; Ambi, S.V.; Sekaran, S.; Krishnan, U.M. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie 2020, 179, 85–100. [Google Scholar] [CrossRef] [PubMed]
  14. Wilson, O.W.A.; Zou, Z.H.; Bopp, M.; Bopp, C.M. Comparison of obesity classification methods among college students. Obes. Res. Clin. Pract. 2019, 13, 430–434. [Google Scholar] [CrossRef]
  15. Parasher, A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad. Med. J. 2021, 97, 312–320. [Google Scholar] [CrossRef]
  16. Homson, W.M.; He, S.L.; Elani, H.W. Self-report oral health and disease experience among adults in China and NZ. Clin. Oral Investig. 2019, 23, 2123–2128. [Google Scholar] [CrossRef]
  17. Available online: https://www.pordata.pt/censos/resultados/populacao-beira+baixa-538 (accessed on 1 October 2023).
  18. Wiertz, C.M.H.; Hemmen, B.; Sep, S.J.S.; van Santen, S.; van Horn, Y.Y.; van Kuijk, S.M.J.; Verbunt, J.A. Life after COVID-19: The road from intensive care back to living—A prospective cohort study. BMJ Open 2022, 12, e062332. [Google Scholar] [CrossRef]
  19. Kowalkowska, J.; Poínhos, R.; Franchini, B.; Afonso, C.; Correia, F.; Pinhão, S.; Vaz de Almeida, M.D.; Rodrigues, S. General and abdominal adiposity in a representative sample of Portuguese adults: Dependency of measures and socio-demographic factors' influence. Br. J. Nutr. 2016, 115, 185–192. [Google Scholar] [CrossRef]
  20. Henriques, A.; Azevedo, A.; Lunet, N.; Moura-Ferreira, P.; do Carmo, I.; Silva, S. Obesity-related knowledge and body mass index: A national survey in Portugal. Eat. Weight. Disord. EWD 2020, 25, 1437–1446. [Google Scholar] [CrossRef]
  21. Rodrigues, F.; Coelho, P. Condições Teórico Práticas das Ciências da Saúde no Brasil 3; Atena Editores: Rio de Janeiro, Brazil, 2020. [Google Scholar] [CrossRef]
  22. Silva, L.; Cunha, D.; Lopes, J.; Ramalheira, J.; Freire, M.; Novio, S.; Nunez, M.J.; Mendonca, D.; Martins-da-Silva, A. Co-morbidities and sleep apnoea severity. A study in a cohort of Portuguese patients. Comorbilidades y gravedad de la apnea del sueño. Estudio en una cohorte de pacientes portugueses. Rev. Neurol. 2016, 62, 433–438. [Google Scholar]
  23. Barros, R.; Moreira, P.; Padrão, P.; Teixeira, V.H.; Carvalho, P.; Delgado, L.; Moreira, A. Obesity increases the prevalence and the incidence of asthma and worsens asthma severity. Clin. Nutr. 2017, 36, 1068–1074. [Google Scholar] [CrossRef] [PubMed]
  24. Cunha, M.; Gaspar, R.; Fonseca, S.; Almeida, D.; Silva, M.; Nunes, L. Implications of literacy for health for body mass index. Aten. Primaria 2014, 46 (Suppl. S5), 180–186. [Google Scholar] [CrossRef] [PubMed]
  25. Sallam, M.; Al-Sanafi, M.; Sallam, M. A Global Map of COVID-19 Vaccine Acceptance Rates per Country: An Updated Concise Narrative Review. J. Multidiscip. Healthc. 2022, 15, 21–45. [Google Scholar] [CrossRef] [PubMed]
  26. Zhou, Y.; Chi, J.; Lv, W.; Wang, Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19). Diabetes/Metab. Res. Rev. 2021, 37, e3377. [Google Scholar] [CrossRef]
  27. Yu, W.; Rohli, K.E.; Yang, S.; Jia, P. Impact of obesity on COVID-19 patients. J. Diabetes Its Complicat. 2021, 35, 107817. [Google Scholar] [CrossRef]
  28. Westheim, A.J.F.; Bitorina, A.V.; Theys, J.; Shiri-Sverdlov, R. COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2021, 22, e13313. [Google Scholar] [CrossRef]
  29. Chagla, Z. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose. Ann. Intern. Med. 2021, 174, JC15. [Google Scholar] [CrossRef]
  30. Omer, S.B.; Benjamin, R.M.; Brewer, N.T.; Buttenheim, A.M.; Callaghan, T.; Caplan, A.; Carpiano, R.M.; Clinton, C.; DiResta, R.; Elharake, J.A.; et al. Promoting COVID-19 vaccine acceptance: Recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet 2021, 398, 2186–2192. [Google Scholar] [CrossRef]
  31. Mohamed, K.; Rzymski, P.; Islam, M.S.; Makuku, R.; Mushtaq, A.; Khan, A.; Ivanovska, M.; Makka, S.A.; Hashem, F.; Marquez, L.; et al. COVID-19 vaccinations: The unknowns, challenges, and hopes. J. Med. Virol. 2022, 94, 1336–1349. [Google Scholar] [CrossRef]
  32. Olusanya, O.A.; Bednarczyk, R.A.; Davis, R.L.; Shaban-Nejad, A. Addressing Parental Vaccine Hesitancy and Other Barriers to Childhood/Adolescent Vaccination Uptake During the Coronavirus (COVID-19) Pandemic. Front. Immunol. 2021, 12, 663074. [Google Scholar] [CrossRef]
  33. Available online: https://www.pordata.pt/censos/resultados/populacao-portugal-361 (accessed on 15 September 2023).
  34. Kolb, J.J.; Radin, J.M.; Quer, G.; Rose, A.H.; Pandit, J.A.; Wiedermann, M. Prevalence of Positive COVID-19 Test Results Collected by Digital Self-report in the US and Germany. JAMA Netw. Open 2023, 6, e2253800. [Google Scholar] [CrossRef] [PubMed]
  35. Rashedi, J.; Mahdavi Poor, B.; Asgharzadeh, V.; Pourostadi, M.; Samadi Kafil, H.; Vegari, A.; Tayebi-Khosroshahi, H.; Asgharzadeh, M. Risk Factors for COVID-19. Infez. Med. 2020, 28, 469–474. [Google Scholar]
  36. Contreras, P.J.; Romero-Albino, Z.; Cuba-Fuentes, M.S. Description of frequent and persistent symptoms of COVID-19 among older adults who attend senior centers. Descripción de síntomas frecuentes y persistentes de COVID-19 en asistentes a centros del adulto mayor. Medwave 2022, 22, e8689. [Google Scholar] [CrossRef] [PubMed]
  37. De Leeuw, A.J.M.; Oude Luttikhuis, M.A.M.; Wellen, A.C.; Müller, C.; Calkhoven, C.F. Obesity and its impact on COVID-19. J. Mol. Med. 2021, 99, 899–915. [Google Scholar] [CrossRef] [PubMed]
  38. Popkin, B.M.; Du, S.; Green, W.D.; Beck, M.A.; Algaith, T.; Herbst, C.H.; Alsukait, R.F.; Alluhidan, M.; Alazemi, N.; Shekar, M. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2020, 21, e13128. [Google Scholar] [CrossRef]
  39. Belchior-Bezerra, M.; Lima, R.S.; Medeiros, N.I.; Gomes, J.A.S. COVID-19, obesity, and immune response 2 years after the pandemic: A timeline of scientific advances. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2022, 23, e13496. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Coelho, P.; Martins, M.; Gavinhos, C.; Liberal, J.; Cabral, E.; Ribeiro, I.; Rodrigues, F. Relationship between BMI and COVID-19. COVID 2023, 3, 1698-1706. https://doi.org/10.3390/covid3110117

AMA Style

Coelho P, Martins M, Gavinhos C, Liberal J, Cabral E, Ribeiro I, Rodrigues F. Relationship between BMI and COVID-19. COVID. 2023; 3(11):1698-1706. https://doi.org/10.3390/covid3110117

Chicago/Turabian Style

Coelho, Patrícia, Manuel Martins, Catarina Gavinhos, Joana Liberal, Ema Cabral, Inês Ribeiro, and Francisco Rodrigues. 2023. "Relationship between BMI and COVID-19" COVID 3, no. 11: 1698-1706. https://doi.org/10.3390/covid3110117

Article Metrics

Back to TopTop